These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12735213)

  • 1. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma.
    Dammacco F; Luccarelli G; Prete M; Silvestris F
    Rev Clin Exp Hematol; 2002; Suppl 1():32-8. PubMed ID: 12735213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma.
    Silvestris F; Cafforio P; Grinello D; Dammacco F
    Rev Clin Exp Hematol; 2002; Suppl 1():39-46. PubMed ID: 12735214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia in multiple myeloma.
    Ludwig H; Pohl G; Osterborg A
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rHuEPO and treatment outcomes: the preclinical experience.
    Ludwig H
    Oncologist; 2004; 9 Suppl 5():48-54. PubMed ID: 15591422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
    Holley JL; Nolan TA; Piraino B
    Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin alfa as a supportive measure in hematologic malignancies.
    Straus DJ
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):25-31. PubMed ID: 12447849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cancer-related anemia with epoetin alfa: a review.
    Ferrario E; Ferrari L; Bidoli P; De Candis D; Del Vecchio M; De Dosso S; Buzzoni R; Bajetta E
    Cancer Treat Rev; 2004 Oct; 30(6):563-75. PubMed ID: 15325036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.
    Ludwig H; Pecherstorfer M; Leitgeb C; Fritz E
    Stem Cells; 1993 Sep; 11(5):348-55. PubMed ID: 8241947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
    Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
    Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.